#nccn ผลการค้นหา

CCHIO 2025 | CACA–NCCN Summit: Advancing Global Standards in Cancer Care mediamedic.co/integrating-ch… linkedin.com/pulse/integrat… #CCHIO2025 #CACA #NCCN #GlobalOncology #CancerGuidelines #OncologyCollaboration

Follicular #Lymphoma (FL)🎗️ #NCCN 1st-line: 💊 Benda + O/R 💉 CHOP + O/R 💊 R-CVP 🧬 R² (Len + R) 2nd-line: 🔄 CHOP / CVP + O/R 🔄 Len + R 🧪 Tafasitamab + Len + R 3rd-line+: 🧬 Bispecifics (Epcoritamab, Mosunetuzumab) 🧫 Tazemetostat 🧲 CAR-T (Axi-cel, Liso-cel, Tisa-cel)

🧬 NCCN 2025 – Frontline CLL ⭐ Preferred regimens: 🔹 BCL2i-based: Venetoclax + Obinutuzumab 🔹 cBTKi-based: Acalabrutinib ± Obinutuzumab, Zanubrutinib 💊 Other options: Venetoclax + Ibrutinib, Ibrutinib ± anti-CD20 🧠 FCR still for young, IGHV-mutated CLL (<65 yrs) #CLL #NCCN

Katy Winckworth-Prejsnar shares how @NCCN is adapting its oncology guidelines for global use. Watch the clip 🎥 : youtu.be/GYKqsiKxrig #Oncology #GlobalHealth #NCCN #CancerCare #OncologySpotlight #Oncoalert #NCCNguidelines

#NCCN distress screening; PHQ4 in infusion center

27) So that brings us to sequencing of potential therapies for MF and especially for #MF-associated #anaemia. Here are two views AND the current #NCCN guidance: nccn.org/guidelines/gui…

26) Despite missing its primary endpoint, #luspatercept is included in #NCCN guidelines as a category 2A option for #MF-associated anaemia, esp for those with symptomatic splenomegaly on a #JAKi, reflecting expert consensus & clinical need rather than FDA approval.

📖 Fast access to NCCN treatment protocols: Now in @ONCOassist . Browse by cancer type, site, or pathway in seconds. #ONCOassist #NCCN #CancerGuidelines #OncologyTools #ClinicalOncology @NCCN

Digital Innovation Transforms Breast Cancer Care: NCCN Launches Interactive Guidelines Navigator bit.ly/3ITaqRp Read now at PatientWorthy.com #PatientWorthy #BreastCancer #NCCN

Exciting news: #taletrectinib (Ibtrozi) gains FDA approval and #NCCN preferred status in ROS1‑positive #NSCLC. Strong efficacy in TRUST-I/II and proven brain penetration. A new era of precision care begins. Learn more: hubs.ly/Q03M6rh80

⏩ The #FDA often approves new cancer drugs through expedited programs despite having uncertainties, such as long-term benefits. But 🆕 data from @JAMA_current show #NCCN guidelines and medical journals rarely highlight uncertainties about these drugs. bit.ly/429yqq9

1/3 🫁IMpower-150 : Sub-group analysis 🫁 🌟 From FLAURA To IMpower-150 Sequential Therapy. ⚠️ This is an IMO, so please take it as a reference. ⚠️ 🌟 It’s recommended in the #NCCN, #ESMO, Japan Lung Cancer Society guidelines. #JLCS 🫁 PFS 🫁

Nadeem R. Abu-Rustum, MD, FACOG, FACS, Chief of the Gynecologic Service at Memorial Sloan Kettering Cancer Center, was honored with the 2025 #NCCN Excellence in Engagement Award. ow.ly/C3VV50X2ZFV

Thanks @Sam4District14 for mentioning the work of the MCCCC task force and the need for more oncologists in the state, especially in the Delta. Look forward to working with you to help resolve concerns around cancer care in the state. #asco #nccn #nosn #coa

🚨 More than 75% of #FDA identified uncertainties about new #cancer drugs do not get published in medical journals and #NCCN guidelines. “There’s big evidence gaps that are not being communicated,” Avi Cherla, MSc @harvardmed @HarvardPilgrim told Healio. bit.ly/429yqq9

New #NCCN guidelines recommend lurbinectedin with atezolizumab as a first-line maintenance therapy for extensive-stage #SCLC, enhancing treatment options. hubs.li/Q03Kld130

#FollicularLymphoma (FL) Later-Line Therapy #NCCN Maintenance: •Rituximab q8–12w× 2yr •Obinutuzumab (ritux-refractory) Consolidation:Auto-SCT 3rd-line+: •Bispecifics: Epcoritamab, Mosunetuzumab •CAR-T: Axi-cel, Liso-cel,Tisa-cel •Tazemetostat, Zanubrutinib+ Obinutuzumab

🧬 NCCN 2025 – Frontline CLL ⭐ Preferred regimens: 🔹 BCL2i-based: Venetoclax + Obinutuzumab 🔹 cBTKi-based: Acalabrutinib ± Obinutuzumab, Zanubrutinib 💊 Other options: Venetoclax + Ibrutinib, Ibrutinib ± anti-CD20 🧠 FCR still for young, IGHV-mutated CLL (<65 yrs) #CLL #NCCN

✅️Myelofibrosis MF Silde1 ➡️NCCN Guidelines management algorithm Slide2 ➡️drug choice according to presentation 🌍 #Myelofibrosis #hematology #NCCN #Guidelines

سعدت بالمشاركه في اللجنه المسئوله عن أصدار التحديثات للشبكة العالمية لعلاج أورام_القولون_والمستقيم الخاصه بمنطقه الشرق الأوسط وشمال أفريقيا #CancerCare #NCCN #ColorectalSurgery #MENA #Oncology #MedicalGuidelines #ProudContributor

Follicular #Lymphoma (FL)🎗️ #NCCN 1st-line: 💊 Benda + O/R 💉 CHOP + O/R 💊 R-CVP 🧬 R² (Len + R) 2nd-line: 🔄 CHOP / CVP + O/R 🔄 Len + R 🧪 Tafasitamab + Len + R 3rd-line+: 🧬 Bispecifics (Epcoritamab, Mosunetuzumab) 🧫 Tazemetostat 🧲 CAR-T (Axi-cel, Liso-cel, Tisa-cel)

🫁 #NCCN guideline updated 🫁 🫁 #NSCLC 🫁 🌟 Version 10.2024 — September 23, 2024 🌟 @NCCN #lungcancer #NSCLC

Ready to advocate for patients 💪🏽 #NCCN @UCLAradonc

🫁 #NSCLC 🫁 🌟 #NCCN Guidelines Update🌟 📌 #Repotrectinib for #NTRK fusion is listed. @NCCN @NTRKers #LCSM #lungcancer

🫁 #NCCN guideline Update 🫁 🫁 #NSCLC 🫁 🌟 Version 11.2024 — October 15, 2024 🌟 @NCCN URL　 x.gd/fP0AI #LungCancer #NSCLC #LCSM

Congratulations on your astonishing achievement! 🎉🥳 #NCCN #MENA_Nccn @NCCN @JNCCN

#MCL First-Line Therapy (#NCCN 2025) Aggressive induction: LyMa, NORDIC, TRIANGLE, R-DHAP + BTKi Less aggressive: Bendamustine-R, VR-CAP, R-CHOP Maintenance: • After intensive Tx: BTKi x2 yrs + rituximab •After R-CHOP: Rituximab q8w x 2–3 yrs #MantleCellLymphoma #Hematology

NCCN 2025 | CLL Dual Refractory Options For relapsed CLL after BTKi + venetoclax: Preferred: CAR-T (Lisocabtagene) ncBTKi (e.g., pirtobrutinib) Other Options: Duvelisib, Ibrutinib/Venetoclax Lenalidomide, FCR Bendamustine + RTX #CLL #Leukemia #NCCN #HemeOnc

Digital Innovation Transforms Breast Cancer Care: NCCN Launches Interactive Guidelines Navigator bit.ly/3ITaqRp Read now at PatientWorthy.com #PatientWorthy #BreastCancer #NCCN

1/3 🫁IMpower-150 : Sub-group analysis 🫁 🌟 From FLAURA To IMpower-150 Sequential Therapy. ⚠️ This is an IMO, so please take it as a reference. ⚠️ 🌟 It’s recommended in the #NCCN, #ESMO, Japan Lung Cancer Society guidelines. #JLCS 🫁 PFS 🫁

#CLL/#SLL Richter Transformation #NCCN 2025 CIT options: • EPOCH-R, R-CHOP, HyperCVAD ± rituximab • Venetoclax + R-CHOP (Cat 2B) If CIT not preferred: • Checkpoint inhibitors (Nivolumab, Pembrolizumab) ± ibrutinib • Pirtobrutinib, Zanubrutinib + Tislelizumab, Acalabrutinib

I start a new chapter as an Oncology Scientist/Medical Writer at @NCCN - @DrBaileeSliker @CD_AACR oncodaily.com/74261.html #Cancer #CancerDiscovery #NCCN #OncoDaily #Oncology

Roadmap to diagnosing all causes of hemolytic anemia - @AaronGoodman33 @ASCO #Cancer #NCCN #OncoDaily #Oncology #UniversityofCalifornia oncodaily.com/url/123380.html

🌟 Update #NCCN Guidelines #NSCLC 🫁 It was published on February 9. It is changing fast. @NCCN #NSCLC

it is a pleasure to see our 3 chronic myeloid leukemia (CML) papers cited in the latest version of NCCN guidelines on CML 🤓🔥😎 @JNCCN @NCCN #NCCN #leusm #CMLsm 👉jnccn.org/view/journals/…

Het Parlement keurde zojuist de ETIAS-wet goed. Deze wet voorziet in de oprichting van de nationale ETIAS-eenheid binnen het National Travel Targeting Center van het NCCN. 🇪🇺 Weet jij al wat de ETIAS-verordening inhoudt? Meer info: bit.ly/3PGOk4K #NCCN #NTTC #ETIAS